Biotechnology News and Research

RSS

Scientists develop algorithm to predict gene sequence of kinases

Kinexus Bioinformatics Corporation, a world-leader in molecular communications research, announced major advancements in its PhosphoNET KnowledgeBase for the study of cell signalling systems. This free resource to the scientific community now features data on more than 92,000 human phosphorylation sites, including their occurrence in over 20 other diverse species, and identification of the protein kinases that target these regulatory sites.

9 Jun 2010

Repligen's fiscal 2010 total revenue decreases to $20,971,000

Repligen Corporation today reported results for the fourth quarter and fiscal year 2010, ended March 31, 2010. Total revenue for the year was $20,971,000 compared to total revenue of $29,362,000 for fiscal year 2009 ended March 31, 2009.

9 Jun 2010

Discovery Labs reports preliminary results from Surfaxin Phase 2 trial in children with Acute Respiratory Failure

Discovery Laboratories, Inc., reports preliminary results from its Phase 2 clinical trial of Surfaxin® in children with Acute Respiratory Failure (ARF), a critical condition often caused in children by severe respiratory infections. The objective of the study was to evaluate the safety and tolerability of intratracheal administration of Surfaxin and to assess whether Surfaxin treatment could decrease the duration of mechanical ventilation in children with ARF.

9 Jun 2010

Resverlogix' RVX-208 increases plasma levels of Apolipoprotein A-I and HDL-cholesterol

Resverlogix is pleased to announce that it has collaborated with the Division of Cardiology at the Research Institute of the McGill University Health Centre (RI of the MUHC), to publish today in the Journal of American College of Cardiology (JACC), a report entitled 'RVX-208 A Small Molecule that Increases Apolipoprotein A-I and High Density Lipoprotein Cholesterol In Vitro and In Vivo'.

9 Jun 2010

NWBT announces release of new detailed report by Pharmaceuticals and Biotech Analyst

Northwest Biotherapeutics, Inc., developer of the DCVax personalized cancer vaccine, today announced the release of a new detailed report by Pharmaceuticals and Biotech Analyst Dr. Navid Malik of the London-based Matrix Group.

9 Jun 2010

Multiple presentations on nab-driven chemotherapy at 46th ASCO

Abraxis BioScience, Inc. presented abstracts describing 10 trials of nanoparticle albumin bound (nab®) driven chemotherapy, nab-paclitaxel (ABRAXANE® for Injectable Suspension; paclitaxel albumin protein-bound particles for injectable suspension), for the treatment of breast cancer at the 46th Annual Meeting of the American Society of Clinical Oncology (ASCO) in Chicago.

9 Jun 2010

Myriad Pharmaceuticals announces strategic initiatives to focus on oncology pipeline

Myriad Pharmaceuticals, Inc. today announced several strategic initiatives to focus the Company's efforts on its oncology pipeline and to conserve its financial resources to extend the Company's projected cash runway beyond 2013.

9 Jun 2010

Takara Bio to distribute NuGEN's solutions in Japan, South Korea, China

NuGEN, the provider of innovative RNA and DNA sample preparation technologies that enable breakthrough genomic analysis, today announced it has signed a non-exclusive agreement with Takara Bio to distribute the full spectrum of NuGEN's next-generation sequencing, microarray and q-PCR nucleic acid amplification and sample preparation products in Japan, South Korea and China. In addition, Takara is authorized to offer services using NuGEN products in the same territory.

9 Jun 2010

Astellas Pharma acquires OSI Pharmaceuticals for $4.0 billion

Astellas Pharma Inc. announced today that the company has completed its acquisition of OSI Pharmaceuticals, Inc. for $4.0 billion.

9 Jun 2010

DSM commences cGMP-manufacturing of Novacta's C. difficile compound

DSM BioSolutions today announced that it has entered into an agreement with Novacta Biosystems Limited, Welwyn Garden City, UK, for the process development and cGMP production of its C. difficile molecule, a new class of lantibiotic compounds.

9 Jun 2010

$Pivotal trial data of zalutumumab in refractory head and neck cancer patients presented at ASCO 2010$

Pivotal trial data of zalutumumab in refractory head and neck cancer patients presented at ASCO 2010

Genmab A/S announced today that data from the pivotal trial of zalutumumab in refractory head and neck cancer patients will be presented today at the 2010 American Society of Clinical Oncology Annual Meeting, which will be held June 1-8 in Chicago, Illinois. This is the first controlled study to demonstrate that an EGFr-targeted antibody given as monotherapy induces a clinically meaningful improvement in progression free survival in patients with refractory head and neck cancer who have failed platinum-based chemotherapy.

9 Jun 2010

Tel Aviv University researchers invent new tool to control risk of runaway stem cells

Stem cell research holds promise for improving the quality of human life ― especially embryonic stem cells, which can potentially develop into any tissue in the human body. However, basic scientific problems still remain unresolved -- but Tel Aviv University researchers are leading the way to inventive solutions.

9 Jun 2010

Lytix Biopharma, KAEL-GemVax granted approval for GV1001/LTX-315 combination cancer therapy study

The Norwegian biopharmaceutical company Lytix Biopharma and Korean company KAEL-GemVax today announced approval by the Norwegian Medicines Agency ('Statens Legemiddelverk') to test a combination of LTX-315 and GV1001 as vaccine therapy in patients with resected tumours. Lytix Biopharma CEO Gunnar Salid states, "We are delighted to announce the approval of our joint study to test a combination of two very interesting experimental drugs.

9 Jun 2010

LAB Research completes exclusive radiotherapy partnership with DMV

LAB Research Inc., a Canadian-based global non-clinical contract research organization, today announced that it has completed an exclusive radiotherapy partnership with DMV Veterinary Centre creating a dedicated research platform.

9 Jun 2010

Discovery Labs receives FDA guidance to gain Surfaxin approval for RDS in premature infants

Discovery Laboratories, Inc. announces today that it has received written guidance from the U.S. Food and Drug Administration (FDA) that is consistent with its ongoing, comprehensive preclinical program to resolve the sole remaining chemistry, manufacturing & control (CMC) issue necessary to potentially gain FDA marketing approval for Surfaxin® (lucinactant) for the prevention of Respiratory Distress Syndrome (RDS) in premature infants.

9 Jun 2010

Insulin delivery devices help diabetic patients optimize blood glucose control, minimize chronic health problems

The growing use of insulin delivery devices such as pens and pumps may help individuals with diabetes optimize blood glucose control and minimize their risk for chronic health problems associated with diabetes, as described in a Special Supplement to Diabetes Technology & Therapeutics, a peer-reviewed journal published by Mary Ann Liebert, Inc.

9 Jun 2010

PharmaMar commences Aplidin Phase III registration trial for multiple myeloma

PharmaMar SA today announced that a registration trial in relapsed/refractory multiple myeloma patients has been initiated with Aplidin(R) (plitidepsin) in combination with dexamethasone versus dexamethasone alone.

9 Jun 2010

Cellectis bioresearch, Lonza collaborate in development, commercialization of bioengineered cell line

Cellectis bioresearch, the French genome customization specialist and a commercial subsidiary of Cellectis, and Lonza, a world leader in biotechnology production, announce today that the companies have entered into an agreement for the development and commercialization of a bioengineered cell line.

9 Jun 2010

Biogen, Elan launch My MS Health, a web-based PRO research program

Biogen Idec and Elan Corporation, plc, in collaboration with EPI-Q, Inc. and Avatar International, LLC, today announced the launch of My MS Health, a first-of-its-kind, web-based, patient-reported outcomes research program. My MS Health is designed to track and provide instant reports on patient function and quality of life using validated measures over time.

9 Jun 2010

NanoViricides anti-HIV drug candidates demonstrate efficacy in cell culture studies with HIV-1 isolates

NanoViricides, Inc. reports that its anti-HIV drug candidates demonstrated efficacy in the recently completed cell culture studies using two distinctly different HIV-1 isolates. The studies were performed in the laboratory of Carol Lackman-Smith at the Southern Research Institute, Frederick, Maryland.

8 Jun 2010

Biotechnology News and Research

Scientists develop algorithm to predict gene sequence of kinases

Repligen's fiscal 2010 total revenue decreases to $20,971,000

Discovery Labs reports preliminary results from Surfaxin Phase 2 trial in children with Acute Respiratory Failure

Resverlogix' RVX-208 increases plasma levels of Apolipoprotein A-I and HDL-cholesterol

NWBT announces release of new detailed report by Pharmaceuticals and Biotech Analyst

Multiple presentations on nab-driven chemotherapy at 46th ASCO

Myriad Pharmaceuticals announces strategic initiatives to focus on oncology pipeline

Takara Bio to distribute NuGEN's solutions in Japan, South Korea, China

Astellas Pharma acquires OSI Pharmaceuticals for $4.0 billion

DSM commences cGMP-manufacturing of Novacta's C. difficile compound

Pivotal trial data of zalutumumab in refractory head and neck cancer patients presented at ASCO 2010

Tel Aviv University researchers invent new tool to control risk of runaway stem cells

Lytix Biopharma, KAEL-GemVax granted approval for GV1001/LTX-315 combination cancer therapy study

LAB Research completes exclusive radiotherapy partnership with DMV

Discovery Labs receives FDA guidance to gain Surfaxin approval for RDS in premature infants

Insulin delivery devices help diabetic patients optimize blood glucose control, minimize chronic health problems

PharmaMar commences Aplidin Phase III registration trial for multiple myeloma

Cellectis bioresearch, Lonza collaborate in development, commercialization of bioengineered cell line

Biogen, Elan launch My MS Health, a web-based PRO research program

NanoViricides anti-HIV drug candidates demonstrate efficacy in cell culture studies with HIV-1 isolates

Biotechnology eBook

Designing fluidic architecture for scalable diagnostic platforms

Evaluating new approaches for rare disease genomics

Expanding access to NMR with the Fourier 80 Duo

Latest News